These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21674569)

  • 1. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
    Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
    J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
    Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
    ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
    Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
    Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
    Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
    Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
    Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids: novel medicines for the treatment of Huntington's disease.
    Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats.
    Fadda P; Robinson L; Fratta W; Pertwee RG; Riedel G
    Neuropharmacology; 2004 Dec; 47(8):1170-9. PubMed ID: 15567426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia.
    Ryan D; Drysdale AJ; Pertwee RG; Platt B
    Neurosci Lett; 2006 Nov; 408(3):236-41. PubMed ID: 16997463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phytocannabinoids as novel therapeutic agents in CNS disorders.
    Hill AJ; Williams CM; Whalley BJ; Stephens GJ
    Pharmacol Ther; 2012 Jan; 133(1):79-97. PubMed ID: 21924288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
    Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
    Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
    Malone DT; Jongejan D; Taylor DA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.
    Valdeolivas S; Navarrete C; Cantarero I; Bellido ML; Muñoz E; Sagredo O
    Neurotherapeutics; 2015 Jan; 12(1):185-99. PubMed ID: 25252936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
    Russo EB; Guy GW; Robson PJ
    Chem Biodivers; 2007 Aug; 4(8):1729-43. PubMed ID: 17712817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
    De Petrocellis L; Vellani V; Schiano-Moriello A; Marini P; Magherini PC; Orlando P; Di Marzo V
    J Pharmacol Exp Ther; 2008 Jun; 325(3):1007-15. PubMed ID: 18354058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.
    Cluny NL; Naylor RJ; Whittle BA; Javid FA
    Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):150-6. PubMed ID: 18816298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.